tiprankstipranks
Disc Medicine, Inc. (IRON)
NASDAQ:IRON
US Market
IRON
Disc Medicine
RESEARCH TOOLSreports
Want to see IRON full AI Analyst Report?

Disc Medicine (IRON) Stock Forecast & Price Target

568 Followers
See the Price Targets and Ratings of:

IRON Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Disc
Medicine
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IRON Stock 12 Month Forecast

Average Price Target

$98.86
▲(33.37% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Disc Medicine in the last 3 months. The average price target is $98.86 with a high forecast of $125.00 and a low forecast of $83.00. The average price target represents a 33.37% change from the last price of $74.12.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"50":"$50","69":"$69","88":"$88","107":"$107","126":"$126"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$125.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":98.85714285714286,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$98.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$83.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[50,69,88,107,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.95,78.8,82.65,86.5,90.35,94.2,98.05,101.9,105.75,109.6,113.45,117.3,121.15,{"y":125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.95,76.78901098901099,78.62802197802198,80.46703296703296,82.30604395604396,84.14505494505495,85.98406593406594,87.82307692307693,89.66208791208791,91.50109890109891,93.34010989010989,95.17912087912089,97.01813186813187,{"y":98.85714285714286,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.95,75.56923076923077,76.18846153846154,76.8076923076923,77.42692307692307,78.04615384615384,78.66538461538461,79.28461538461539,79.90384615384616,80.52307692307693,81.1423076923077,81.76153846153846,82.38076923076923,{"y":83,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":51.13,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.97,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.69,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.41,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.65,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.54,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.78,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.91,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.97,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.95,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$125.00Average Price Target$98.86Lowest Price Target$83.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wedbush Analyst forecast on IRON
David Nierengarten
Wedbush
Wedbush
$88
Buy
18.73%
Upside
Reiterated
07/31/26
Wedbush Sticks to Its Buy Rating for Disc Medicine (IRON)
Truist Financial Analyst forecast on IRON
Danielle Brill
Truist Financial
Truist Financial
$83
Buy
11.98%
Upside
Reiterated
07/31/26
Truist Financial Reaffirms Their Buy Rating on Disc Medicine (IRON)
Stifel Nicolaus Analyst forecast on IRON
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
$111
Buy
49.76%
Upside
Reiterated
07/31/26
Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON), Mettler-Toledo (NYSE: MTD) and Moderna (NASDAQ: MRNA)
LifeSci Capital Analyst forecast on IRON
Rami Katkhuda
LifeSci Capital
LifeSci Capital
$100
Buy
34.92%
Upside
Reiterated
07/30/26
Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON) and Alnylam Pharma (NASDAQ: ALNY)
TD Cowen Analyst forecast on IRON
Tara Bancroft
TD Cowen
TD Cowen
―
Buy
―
Reiterated
07/30/26
Analysts' Top Healthcare Picks: Tvardi Therapeutics (TVRD), Disc Medicine (IRON)
Morgan Stanley Analyst forecast on IRON
Sean Laaman
Morgan Stanley
Morgan Stanley
$80→$85
Buy
14.68%
Upside
Assigned
06/16/26
Disc Medicine price target raised to $85 from $80 at Morgan StanleyDisc Medicine price target raised to $85 from $80 at Morgan Stanley
H.C. Wainwright Analyst forecast on IRON
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
―
Buy
―
Reiterated
06/08/26
H.C. Wainwright Remains a Buy on Disc Medicine (IRON)
Leerink Partners Analyst forecast on IRON
Thomas Smith
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON), Molecular Partners (NASDAQ: MOLN) and Park Dental Partners, Inc. (NASDAQ: PARK)
BMO Capital Analyst forecast on IRON
Evan Seigerman
BMO Capital
BMO Capital
$100
Buy
34.92%
Upside
Reiterated
06/02/26
Disc Medicine: Outperform Rating Reiterated as Advancing Rare-Hematology Pipeline Supports Unchanged $100 Price Target
Cantor Fitzgerald Analyst forecast on IRON
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$125
Buy
68.65%
Upside
Reiterated
05/12/26
Cantor Fitzgerald Remains a Buy on Disc Medicine (IRON)
Wells Fargo Analyst forecast on IRON
Derek Archila
Wells Fargo
Wells Fargo
$78→$79
Buy
6.58%
Upside
Reiterated
03/02/26
Disc Medicine price target raised to $79 from $78 at Wells FargoDisc Medicine price target raised to $79 from $78 at Wells Fargo
Raymond James Analyst forecast on IRON
Martin Auster
Raymond James
Raymond James
$78.06→$117
Buy
57.85%
Upside
Reiterated
01/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Disc Medicine (NASDAQ: IRON), Nuvalent (NASDAQ: NUVL) and Roche Holding AG (Other OTC: RHHVF)
Jefferies Analyst forecast on IRON
Roger Song
Jefferies
Jefferies
$154
Buy
107.77%
Upside
Reiterated
12/19/25
Jefferies sees 'overreaction' to article on Disc Medicine's EPP approvabilityJefferies sees 'overreaction' to article on Disc Medicine's EPP approvability
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wedbush Analyst forecast on IRON
David Nierengarten
Wedbush
Wedbush
$88
Buy
18.73%
Upside
Reiterated
07/31/26
Wedbush Sticks to Its Buy Rating for Disc Medicine (IRON)
Truist Financial Analyst forecast on IRON
Danielle Brill
Truist Financial
Truist Financial
$83
Buy
11.98%
Upside
Reiterated
07/31/26
Truist Financial Reaffirms Their Buy Rating on Disc Medicine (IRON)
Stifel Nicolaus Analyst forecast on IRON
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
$111
Buy
49.76%
Upside
Reiterated
07/31/26
Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON), Mettler-Toledo (NYSE: MTD) and Moderna (NASDAQ: MRNA)
LifeSci Capital Analyst forecast on IRON
Rami Katkhuda
LifeSci Capital
LifeSci Capital
$100
Buy
34.92%
Upside
Reiterated
07/30/26
Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON) and Alnylam Pharma (NASDAQ: ALNY)
TD Cowen Analyst forecast on IRON
Tara Bancroft
TD Cowen
TD Cowen
―
Buy
―
Reiterated
07/30/26
Analysts' Top Healthcare Picks: Tvardi Therapeutics (TVRD), Disc Medicine (IRON)
Morgan Stanley Analyst forecast on IRON
Sean Laaman
Morgan Stanley
Morgan Stanley
$80→$85
Buy
14.68%
Upside
Assigned
06/16/26
Disc Medicine price target raised to $85 from $80 at Morgan StanleyDisc Medicine price target raised to $85 from $80 at Morgan Stanley
H.C. Wainwright Analyst forecast on IRON
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
―
Buy
―
Reiterated
06/08/26
H.C. Wainwright Remains a Buy on Disc Medicine (IRON)
Leerink Partners Analyst forecast on IRON
Thomas Smith
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON), Molecular Partners (NASDAQ: MOLN) and Park Dental Partners, Inc. (NASDAQ: PARK)
BMO Capital Analyst forecast on IRON
Evan Seigerman
BMO Capital
BMO Capital
$100
Buy
34.92%
Upside
Reiterated
06/02/26
Disc Medicine: Outperform Rating Reiterated as Advancing Rare-Hematology Pipeline Supports Unchanged $100 Price Target
Cantor Fitzgerald Analyst forecast on IRON
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$125
Buy
68.65%
Upside
Reiterated
05/12/26
Cantor Fitzgerald Remains a Buy on Disc Medicine (IRON)
Wells Fargo Analyst forecast on IRON
Derek Archila
Wells Fargo
Wells Fargo
$78→$79
Buy
6.58%
Upside
Reiterated
03/02/26
Disc Medicine price target raised to $79 from $78 at Wells FargoDisc Medicine price target raised to $79 from $78 at Wells Fargo
Raymond James Analyst forecast on IRON
Martin Auster
Raymond James
Raymond James
$78.06→$117
Buy
57.85%
Upside
Reiterated
01/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Disc Medicine (NASDAQ: IRON), Nuvalent (NASDAQ: NUVL) and Roche Holding AG (Other OTC: RHHVF)
Jefferies Analyst forecast on IRON
Roger Song
Jefferies
Jefferies
$154
Buy
107.77%
Upside
Reiterated
12/19/25
Jefferies sees 'overreaction' to article on Disc Medicine's EPP approvabilityJefferies sees 'overreaction' to article on Disc Medicine's EPP approvability
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Disc Medicine

3 Months
Thomas SmithLeerink Partners
Success Rate
18/22 ratings generated profit
82%
Average Return
+24.71%
Copying Thomas Smith's trades and holding each position for 3 Months would result in 81.82% of your transactions generating a profit, with an average return of +24.71% per trade.
1 Year
Thomas SmithLeerink Partners
Success Rate
18/22 ratings generated profit
82%
Average Return
+30.46%
Copying Thomas Smith's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +30.46% per trade.
2 Years
Thomas SmithLeerink Partners
Success Rate
21/22 ratings generated profit
95%
Average Return
+56.50%
Copying Thomas Smith's trades and holding each position for 2 Years would result in 95.45% of your transactions generating a profit, with an average return of +56.50% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IRON Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
23
16
7
7
7
Buy
15
11
9
18
23
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
38
27
16
25
30
In the current month, IRON has received 30 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IRON average Analyst price target in the past 3 months is 98.86.
Each month's total comprises the sum of three months' worth of ratings.

IRON Financial Forecast

IRON Earnings Forecast

Next quarter’s earnings estimate for IRON is -$1.67 with a range of -$2.14 to -$1.28. The previous quarter’s EPS was -$1.54. IRON beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 36.78% of the time in the same period. In the last calendar year IRON has Performed in-line its overall industry.
Next quarter’s earnings estimate for IRON is -$1.67 with a range of -$2.14 to -$1.28. The previous quarter’s EPS was -$1.54. IRON beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 36.78% of the time in the same period. In the last calendar year IRON has Performed in-line its overall industry.
No data currently available

IRON Sales Forecast

Next quarter’s sales forecast for IRON is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. IRON beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.91% of the time in the same period. In the last calendar year IRON has Performed in-line its overall industry.
Next quarter’s sales forecast for IRON is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. IRON beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.91% of the time in the same period. In the last calendar year IRON has Performed in-line its overall industry.

IRON Stock Forecast FAQ

What is IRON’s average 12-month price target, according to analysts?
Based on analyst ratings, Disc Medicine, Inc.’s 12-month average price target is 98.86.
    What is IRON’s upside potential, based on the analysts’ average price target?
    Disc Medicine, Inc. has 33.37% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IRON a Buy, Sell or Hold?
          Disc Medicine, Inc. has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Disc Medicine, Inc.’s price target?
            The average price target for Disc Medicine, Inc. is 98.86. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $125.00 ,the lowest forecast is $83.00. The average price target represents 33.37% Increase from the current price of $74.12.
              What do analysts say about Disc Medicine, Inc.?
              Disc Medicine, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of IRON?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.